Concepedia

Balakumar Vijayakrishnan

BV

15

Publications

741

Citations

13

H-Index

2009

Active since

Affiliations

University of Oxford(Current)

AstraZeneca (United States)

Spirogen (United Kingdom)

AstraZeneca (United Kingdom)

Balakumar Vijayakrishnan is an author at University of Oxford specializing in medicine, biomolecular engineering, and natural sciences.

ORCID

Top concepts

Publications per year

2009–2024

15

Publications

15

Thiyl Glycosylation of Olefinic Proteins: S‐Linked Glycoconjugate Synthesis

Nicola Floyd, Balakumar Vijayakrishnan, Julia R. Koeppe et al. · Angewandte Chemie International Edition · 2009 · 216 citations

CD25-targeted antibody–drug conjugate depletes regulatory T cells and eliminates established syngeneic tumors via antitumor immunity

Francesca Zammarchi, Karin Havenith, François Bertelli et al. · Journal for ImmunoTherapy of Cancer · 2020 · 77 citations · Full text

TR1801‐ADC: a highly potent cMet antibody–drug conjugate with high activity in patient‐derived xenograft models of solid tumors

Marco Gymnopoulos, Oscar Betancourt, Vincent Blot et al. · Molecular Oncology · 2019 · 66 citations · Full text

An antibacterial vaccination strategy based on a glycoconjugate containing the core lipopolysaccharide tetrasaccharide Hep2Kdo2

Ling Bing Kong, Balakumar Vijayakrishnan, Michael Kowarik et al. · Nature Chemistry · 2016 · 64 citations

, , +10

Potent Fluoro‐oligosaccharide Probes of Adhesion in <i>Toxoplasmosis</i>

Sarah Allman, Henrik H. Jensen, Balakumar Vijayakrishnan et al. · ChemBioChem · 2009 · 62 citations

, , +17

Rows per page

1–5 of 15